Proteins for use in human and animal staphylococcus infections
The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed to Staphylococci.
1. A method of treating or preventing a Staphylococcus infection comprising administering to a subject a composition comprising a polypeptide comprising the sequence as depicted in SEQ ID NO:1 or variant thereof, said variant being:
a) a polypeptide comprising a sequence in which the CBD of SEQ ID NO:1 has been replaced by a CBD domain of another Staphlococci specific endolysin; or
b) a polypeptide comprising the sequence of SEQ ID NO:1 except for at least the first N-terminal amino acid and at most the first 28 N-terminal amino acids of SEQ ID NO:1; or
c) a polypeptide comprising one or more amino acid substitutions in the sequence of SEQ ID NO:1; or
d) a polypeptide comprising in addition to the sequence of SEQ ID NO: 1 sequences representing marker moieties, tags or other functional polypeptide sequences; or
e) a polypeptide comprising one or more additional amino acid residues inserted into the amino acid sequence according to SEQ ID NO:1; or
f) a polypeptide comprising a polypeptide sequence representing any combination of variants a), b), c), d) and e).
2. The method of claim 1 , wherein the Staphylococcus infections results from infections by S. aureus, S. aureus (MRSA), S. epidermidis, S. haemolyticus, S. simulans, S. saprophyticus, S. chromogenes, S. hyicus, S. warneri and/or S. xylosus.
3. The method according to claim 1 , wherein the Staphylococcus infection results in a disease state.
4. The method according to claim 3 , wherein the disease state is bacteremia, endocarditis, keratitis, endoplastitis or bovine mastitis.
5. The method according to claim 1 , wherein the composition is administered topically, orally or by IV injection.